About GTxGTx, in Memphis, Tenn follow to read more ., is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules that selectively target hormone pathways and cancer, osteoporosis. To treat bone loss, muscle loss and other serious diseases GTx developing toremifene citrate, a selective estrogen receptor modulator, or SERM, in two separate clinical programs in men: first, a completed phase III clinical trial evaluating toremifene 80 mg for the treatment of serious side effects of hormonal therapy for advanced prostate cancer, and second, an ongoing Phase III clinical trial evaluating toremifene 20 mg for the prevention of prostate cancer in high risk men with high grade prostatic intraepithelial neoplasia, or PIN. In 2006, GTx and Ipsen Group entered into a development and collaboration agreement for toremifene in all indications except breast cancer for Europe and the Commonwealth of Independent States . GTx is be submitted for marketing approval and, if approved, plans to commercialize toremifene 80 mg in the United States. In December 2007 GTX and Merck & Co. Formed a collaboration to research and develop selective androgen receptor modulators , a new class of drugs that treat the potential sarcopenia to to loss of muscle mass is reduced physical strength and ability, activities of daily living, cancer cachexia , as well as other musculoskeletal cause. Merck and GTx lead several Phase I and Phase II clinical trials evaluating multiple SARM product candidates including Ostarine for sarcopenia. Able II clinical trial for cancer cachexia which will be completed in 2008. Merck and GTx evaluate additional muscle loss indications for potential SARM clinical development. GTx is also the development of their preclinical compounds GTx-758, an oral LH inhibitor for advanced prostate cancer and GTx-878, an estrogen receptor beta agonist for the treatment of benign prostatic hyperplasia and chronic prostatitis.
Hemo – oncology is nothing new in the MRH. It is the second largest stem cell transplantation center in Canada after Toronto General Hospital. Each year, 160 patients received the stem cell transplantation at the MRH.
follow to read more
On Spineinternationally recognized as a the leading journal to its territory of Spine ,, peer-reviewed, bi – weekly, to the to published Genuine posts by sector the spine keeps. It is the leading subspecialty periodical for the treatment of spinal disorders. Only use original documents are for the publication of with a understand that they regarded contributed solely to spine. According to recent ISI Science Citation Impact Factor, spine ranking highest below the general orthopedic periodicals and subspecialty titles Recent the journal website.
To a random telephone interview unidentified Dr. Timothy S. Carey and colleagues of University of North Carolina, Chapel Hill, 732 adults to chronic back pains. The respondents were in more detail on what she ask back pain treatments be used. Rehabilitation Programme not match the Research Evidence.